Semaglutide 2.4 mg weekly injection produced greater average weight loss than liraglutide 3.0 mg daily injection in STEP 8: 15.8% versus 6.4% at 68 weeks. That result applies to the adults and regimens studied, rather than every formulation of either molecule.[1]STEP 8 and SUSTAIN 10 answer different questions; oral semaglutide also has direct comparative evidence from PIONEER 4.
The weight comparison: STEP 8
This open-label trial randomized 338 adults with obesity, or overweight with a weight-related condition, without diabetes. The active groups received semaglutide 2.4 mg weekly (126 people) or liraglutide 3.0 mg daily (127 people), alongside diet and physical-activity counseling. The primary outcome was percentage weight change at week 68: −15.8% versus −6.4%, a difference of −9.4 percentage points (95% CI −12.0 to −6.8).[1]
Gastrointestinal events occurred in 84.1% versus 82.7%; treatment discontinuation for any reason occurred in 13.5% versus 27.6%. The latter is not an adverse-event-only measure. Intolerance handling differed: semaglutide could be reduced to 1.7 mg; liraglutide required stopping, with restarting allowed.[1] The Wegovy versus Saxenda comparison discusses those differences in the context of the two weight-management products. These design details matter when interpreting the results.
The diabetes comparison: SUSTAIN 10
SUSTAIN 10 was an open-label, 30-week trial in 577 adults with type 2 diabetes taking oral glucose-lowering medicines. Semaglutide 1.0 mg weekly reduced HbA1c by 1.7 percentage points versus 1.0 with liraglutide 1.2 mg daily; the estimated difference was −0.69 points (95% CI −0.82 to −0.56). Weight fell 5.8 versus 1.9 kg (estimated difference −3.83 kg, 95% CI −4.57 to −3.09).[2]
This was a comparison of those doses, not maximum-dose therapy or the obesity regimens. Gastrointestinal disorders were more frequent with semaglutide (43.9% versus 38.3%), as were adverse events leading to premature treatment discontinuation (11.4% versus 6.6%).[2]Similar drug classes do not guarantee identical tolerability.
What about tablets?
PIONEER 4 randomized 711 adults with type 2 diabetes to daily oral semaglutide up to 14 mg, liraglutide up to 1.8 mg, or placebo. At week 26, oral semaglutide was noninferior to liraglutide for HbA1c in the primary treatment-policy analysis, and produced greater weight loss (4.4 versus 3.1 kg). This diabetes study does not compare Wegovy 25 mg tablets against Saxenda 3.0 mg.[5]
Swipe to see all columns
| Question | Liraglutide | Semaglutide |
|---|---|---|
| STEP 8 obesity injections | 3.0 mg daily; −6.4% at 68 weeks | 2.4 mg weekly; −15.8% at 68 weeks |
| SUSTAIN 10 diabetes injections | 1.2 mg daily; HbA1c −1.0 points | 1.0 mg weekly; HbA1c −1.7 points |
| PIONEER 4 diabetes comparison | 1.8 mg daily injection | 14 mg daily tablet; HbA1c noninferiority in primary analysis |
| Current weight-management forms | Saxenda daily injection | Wegovy weekly injection or daily adult tablet; adult 7.2 mg injection option under label conditions |
Current Wegovy labeling includes 25 mg daily tablets for adults and a 7.2 mg weekly injection option for adult weight reduction under specified conditions. STEP 8 tested neither. Wegovy injection and Saxenda both include eligible patients aged 12 and older; Saxenda also specifies body weight above 60 kg. Adult trial results do not establish adolescent comparative efficacy.[3][4]
Choosing between the studied options
The injection trials support larger average effects with the semaglutide regimens tested. A personal decision also depends on the condition being treated, prior response, adverse effects, formulation and coverage. Both obesity brands carry thyroid C-cell tumor boxed warnings and MTC/MEN 2 contraindications, plus precautions including pancreatitis, gallbladder disease and severe gastrointestinal reactions.[3][4] A prescriber should assess those factors; the trial averages are not a switching or dosing protocol.
Read the semaglutide trial overview, Ozempic versus Wegovy, or the tirzepatide comparison for the evidence behind other product choices.